Horizon Therapeutics Plc (HZNP)

27.19
NASDAQ : Health Technology
Prev Close 27.68
Day Low/High 27.14 / 28.02
52 Wk Low/High 16.56 / 29.44
Avg Volume 1.96M
Exchange NASDAQ
Shares Outstanding 186.45M
Market Cap 5.16B
EPS -0.50
P/E Ratio 70.97
Div & Yield N.A. (N.A)

Latest News

Horizon Therapeutics Plc Collaborates With Rare Disease Advocates To Elevate Resources And Shared Experiences Through Launch Of #RAREis™ Community Website

Horizon Therapeutics Plc Collaborates With Rare Disease Advocates To Elevate Resources And Shared Experiences Through Launch Of #RAREis™ Community Website

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.

Horizon Therapeutics Plc Reports Strong Second-Quarter 2019 Results;Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics Plc Reports Strong Second-Quarter 2019 Results;Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics plc (Nasdaq: HZNP) today announced its second-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.

Horizon Therapeutics Plc Announces Teprotumumab Expanded Access Program

Horizon Therapeutics Plc Announces Teprotumumab Expanded Access Program

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the availability of an expanded access program for its investigational medicine teprotumumab.

Horizon Therapeutics Plc Appoints Dr. Sue Mahony To Board Of Directors

Horizon Therapeutics Plc Appoints Dr. Sue Mahony To Board Of Directors

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has appointed Dr.

Horizon Therapeutics Plc Wins International CSR Excellence Award For Partnership With Perspectives Math And Science Academy

Horizon Therapeutics Plc Wins International CSR Excellence Award For Partnership With Perspectives Math And Science Academy

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the company has won a Gold International CSR Excellence Award in the Large Business category for its partnership with Chicago-based school, Perspectives Math and Science Academy (MSA).

Horizon Therapeutics Plc To Release Second-Quarter 2019 Financial Results And Host Webcast On Aug. 7, 2019

Horizon Therapeutics Plc To Release Second-Quarter 2019 Financial Results And Host Webcast On Aug. 7, 2019

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug.

Horizon Therapeutics Plc Announces Pricing Of Private Offering Of Senior Notes

Horizon Therapeutics Plc Announces Pricing Of Private Offering Of Senior Notes

Horizon Therapeutics plc (Nasdaq: HZNP) ("Horizon") today announced that Horizon Pharma USA, Inc.

Horizon Therapeutics Plc Announces Proposed Private Offering Of Senior Notes

Horizon Therapeutics Plc Announces Proposed Private Offering Of Senior Notes

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc.

Horizon Therapeutics Plc Submits Teprotumumab Biologics License Application (BLA) For The Treatment Of Active Thyroid Eye Disease (TED)

Horizon Therapeutics Plc Submits Teprotumumab Biologics License Application (BLA) For The Treatment Of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has submitted a Biologics License Application (BLA) to the U.

LaQuilla Shares Her Experience Living With Graves' Disease And Thyroid Eye Disease.

LaQuilla Shares Her Experience Living With Graves' Disease And Thyroid Eye Disease.

Today marks the launch of a new patient empowerment and disease education initiative called Eyes on Graves', created to bring attention, education and resources to people living with Graves' disease and/or thyroid eye disease (TED).

Horizon Therapeutics Plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase Injection) In Combination With Methotrexate To Increase Response Rates And Duration Of Therapy

Horizon Therapeutics Plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase Injection) In Combination With Methotrexate To Increase Response Rates And Duration Of Therapy

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic...

Horizon Therapeutics Plc Highlights The Systemic Implications Of Gout And The Need For Improved Patient Care Strategies With A Series Of Presentations At EULAR 2019

Horizon Therapeutics Plc Highlights The Systemic Implications Of Gout And The Need For Improved Patient Care Strategies With A Series Of Presentations At EULAR 2019

Horizon Therapeutics plc (Nasdaq: HZNP) is elevating the dialogue on gout within the medical and scientific community during the Annual European Congress of Rheumatology (EULAR 2019) with a series of data presentations on gout and its systemic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVA, BWB, CCF, CXW Downgrades: ASH, GCAP, HTH, HZNP, MBTF, MOV, OFED, PBT, WOR Initiations: CUE, EQH, TALO, TMSR Read on to get TheStreet Quant Ratings' detailed report:

Horizon Therapeutics Plc To Participate In The JMP Securities Life Sciences Conference

Horizon Therapeutics Plc To Participate In The JMP Securities Life Sciences Conference

Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in June: The JMP Securities Life Sciences Conference Date: June 20, 2019 Presentation Time: 10 a.

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to...

Horizon Named One Of The Best Workplaces In Chicago By Great Place To Work® And FORTUNE

Horizon Named One Of The Best Workplaces In Chicago By Great Place To Work® And FORTUNE

Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 " Best Workplaces in Chicago" list.

Horizon Therapeutics Plc Launches New Data-Driven Campaign To Reset The Dialogue On Gout

Horizon Therapeutics Plc Launches New Data-Driven Campaign To Reset The Dialogue On Gout

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Gout Lies , a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly...

Horizon Therapeutics Plc Announces Tina Ventura As A Healthcare Businesswomen's Association 2019 Luminary

Horizon Therapeutics Plc Announces Tina Ventura As A Healthcare Businesswomen's Association 2019 Luminary

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary.

Horizon Therapeutics Plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics Plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales And Adjusted EBITDA Guidance

Horizon Therapeutics plc (Nasdaq: HZNP) today announced its first-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.

Horizon Therapeutics Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Therapeutics Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees.

New Data From Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction In Proptosis, Or Eye Bulging, The Main Cause Of Morbidity In Active Thyroid Eye Disease (TED)

New Data From Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction In Proptosis, Or Eye Bulging, The Main Cause Of Morbidity In Active Thyroid Eye Disease (TED)

Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented as part of a...

Horizon Pharma Plc And Gift Of Adoption Announce A New Fund To Facilitate Global Adoptions Of Children With Rare Diseases

Horizon Pharma Plc And Gift Of Adoption Announce A New Fund To Facilitate Global Adoptions Of Children With Rare Diseases

Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the #RAREis Adoption Fund to help facilitate global adoptions of children with rare diseases.

Horizon Pharma Plc To Present Results From Its Phase 3 Teprotumumab Trial (OPTIC) at The 2019 American Association Of Clinical Endocrinologists (AACE) Scientific And Clinical Congress

Horizon Pharma Plc To Present Results From Its Phase 3 Teprotumumab Trial (OPTIC) at The 2019 American Association Of Clinical Endocrinologists (AACE) Scientific And Clinical Congress

Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association...

Horizon Pharma Plc Named One Of The 2019 Best Workplaces In Health Care And Biopharma By FORTUNE And Great Place To Work®

Horizon Pharma Plc Named One Of The 2019 Best Workplaces In Health Care And Biopharma By FORTUNE And Great Place To Work®

Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by Great Place to Work® and  FORTUNE Magazine.

Horizon Pharma Plc To Release First-Quarter 2019 Financial Results And Host Webcast On May 8, 2019

Horizon Pharma Plc To Release First-Quarter 2019 Financial Results And Host Webcast On May 8, 2019

Horizon Pharma plc (Nasdaq: HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019.

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma Plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees.

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma Plc Wins PR News CSR Award For Partnership With Perspectives Math And Science Academy

Horizon Pharma plc (Nasdaq: HZNP) announced today that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy (MSA).

TheStreet Quant Rating: C+ (Hold)